IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Company/Organization Date Area of
Collaboration
Terms of Agreement
Immusol 2005 Target identification Three-year discovery, development and
commercialization agreement to use
Immusol’s gene-activation technology to
discover targets, which Novartis might
elect to use for the development of
pharmaceuticals.
Avalon 2005 Drug discovery Agreement to develop small-molecule
drug using Avalon’s drug-discovery engine
and product candidates in Novartis’
chemical library. Milestone achieved in
January 2008.
Immusol 2005 Drug discovery Three-year discovery, development and
commercialization collaboration. Immusol
will leverage its gene activation technology
to discover biologically validated drug
targets for Novartis.
Idera (formerly Hybridon) 2005 Drug discovery Research collaboration and license deal for
the discovery, optimization, development
and commercialization of Toll-like receptor
9 drug candidates targeting asthma and
allergy based on Hybridon’s proprietary
immune modulatory oligonucleotide (IMO)
technology platform.
Galapagos 2005 Design research
programs
Agreement to use Galapagos’ genomics
services division’s SilenceSelect target
discovery system.
Conor Medsystems 2005 Drug-coated stents Conor will test three Novartis products
(Glivec, Elidel and midostaurin) for use
with future stents for the treatment of
clogged heart arteries. If one of the
compounds proves successful, Conor has
the option to obtain a worldwide,
non-exclusive license to commercialize
products combining the compound and its
stents.
© 2009 IMS Health In cor po rated or its af fil i ates Page 134